LAWRENCE, Mass., Nov. 16, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced new findings demonstrating positive outcomes related to more frequent hemodialysis with the NxStage® System One™. The data will be presented at the American Society of Nephrology (ASN) Kidney Week 2016 Annual Meeting being held November 15-20, 2016, in Chicago. The research was conducted by Dr. Eric D. Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant Professor of Pharmaceutical Care & Health Systems at the University of Minnesota, Dr. Allan J. Collins, NxStage Senior Medical Advisor and Professor of Medicine at the University of Minnesota, and Dr Fredric O. Finkelstein, Clinical Professor of Medicine at Yale University. Conference attendees can meet with NxStage representatives in booth 1135.
Researchers will present data from a number of studies that highlight the benefits of more frequent hemodialysis (typically performed at home) versus conventional in-center hemodialysis, including:
- Better Outcomes and Higher Quality of Life: According to a meta-analysis of randomized clinical trials, significant beneficial effects on left ventricular hypertrophy, blood pressure, phosphorus balance and health-related quality of life;
- Lower Cost of Care: A $10,000 per patient-year decrease in Medicare payments for inpatient care, post-acute care, and physician and supplier services; and,
- Improved Clinical Outcomes in Incident Dialysis Patients: Higher transplant rates and lower death rates for incident dialysis patients on more frequent home hemodialysis.
"Both randomized clinical trials and observational research indicate that frequent home hemodialysis is an efficacious therapy option for dialysis patients, including new patients, patients with key cardiovascular risk factors, and those with poor quality of life," said Dr. Weinhandl. "Importantly, this research also shows that these patients can benefit from this therapy option without burdening the system with increased cost."
"Data continues to reaffirm that more frequent hemodialysis with the System One provides better patient health outcomes at a lower cost of care," said Joe Turk, President of NxStage Medical. "Based upon compelling evidence, more frequent home hemodialysis should be considered the standard of care for a growing number dialysis patients. We are excited to be sharing this data with the entire renal care community and look forward to working together to provide greater patient access to this life-changing therapy option."
Currently, over 95% percent of hemodialysis patients in the U.S. receive treatment three times per week, despite overwhelming evidence of clinical and lifestyle benefits for patients on more frequent hemodialysis. The NxStage System One is a simple, flexible and portable hemodialysis system that provides a wide range of dialysis therapy options, including home, more frequent and nocturnal dialysis. Visit www.nxstage.com for more information on therapy options with the System One.
Dr. Eric Weinhandl will conduct an oral presentation on Thursday, November 17, 2016 at 5:18 p.m. CT. Posters numbers 1114, 1115, 1116, and 1117, will be displayed Saturday, November 19, 2016 from 9:30 a.m. – 2:30 p.m. CT on the scientific exposition floor.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-shows-better-outcomes-higher-quality-of-life-lower-cost-of-care-and-increased-likelihood-for-transplant-with-more-frequent-hemodialysis-using-the-nxstage-system-one-300363937.html
SOURCE NxStage Medical, Inc.